Trial Profile
A non-randomised open-label phase II trial of Caelyx [doxorubicin liposomal] in patients with hepatoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2005
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 03 Aug 2005 New trial record.